[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634818":3},{"organization":4,"outcomesModule":7,"designInfo":41,"detailedDescription":11,"studyPopulation":11,"armGroups":47,"interventions":56,"overallOfficials":64,"centralContacts":67,"locations":75,"responsibleParty":119,"collaborators":11,"id":121,"slug":122,"hasResults":123,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":11,"eligibilityCriteria":127,"healthyVolunteers":128,"sex":129,"minAge":130,"maxAge":131,"enrollmentInfo":132,"targetDuration":11,"studyType":135,"phases":136,"briefSummary":138,"conditions":139,"keywords":141,"overallStatus":78,"whyStopped":11,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":156},{"fullName":5,"class":6},"Bristol-Myers Squibb","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":30,"otherOutcomes":11},[9,13,15,17,20,22,24,26,28],{"measure":10,"description":11,"timeFrame":12},"Maximum Plasma Concentration (Cmax)",null,"Up to Day 17",{"measure":14,"description":11,"timeFrame":12},"Area under the concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)]",{"measure":16,"description":11,"timeFrame":12},"Area under the concentration-time curve from time zero extrapolated to infinite time [AUC(INF)]",{"measure":18,"description":11,"timeFrame":19},"Number of participants with Adverse Events (AE)","Up to approximately day 37",{"measure":21,"description":11,"timeFrame":19},"Number of participants with Serious Adverse Events (AE)",{"measure":23,"description":11,"timeFrame":12},"Number of participants with clinically significant changes in Physical Examinations (PE)",{"measure":25,"description":11,"timeFrame":12},"Number of participants with clinically significant changes in vital signs (VS)",{"measure":27,"description":11,"timeFrame":12},"Number of participants with clinically significant changes in 12-lead ECGs",{"measure":29,"description":11,"timeFrame":12},"Number of participants with clinically significant changes in laboratory tests results",[31,33,35,37,39],{"measure":32,"description":11,"timeFrame":12},"Time of maximum observed drug concentration (Tmax)",{"measure":34,"description":11,"timeFrame":12},"Terminal elimination half-life (T-HALF)",{"measure":36,"description":11,"timeFrame":12},"Apparent total body clearance (CLT\u002FF)",{"measure":38,"description":11,"timeFrame":12},"Apparent volume of distribution during the terminal phase (Vz\u002FF)",{"measure":40,"description":11,"timeFrame":12},"Mean residence time (MRT)",{"allocation":42,"interventionModel":43,"interventionModelDescription":11,"primaryPurpose":44,"observationalModel":11,"timePerspective":11,"maskingInfo":45},"RANDOMIZED","CROSSOVER","TREATMENT",{"masking":46,"maskingDescription":11,"whoMasked":11},"NONE",[48,53],{"label":49,"type":50,"description":11,"interventionNames":51},"Treatment A","EXPERIMENTAL",[52],"Drug: Navlimetostat",{"label":54,"type":50,"description":11,"interventionNames":55},"Treatment B",[52],[57],{"type":58,"name":59,"description":60,"armGroupLabels":61,"otherNames":62},"DRUG","Navlimetostat","Specified dose on specified days",[49,54],[63],"BMS-986504",[65],{"name":5,"affiliation":5,"role":66},"STUDY_DIRECTOR",[68,73],{"name":69,"role":70,"phone":71,"phoneExt":11,"email":72},"BMS Clinical Trials Contact Center www.BMSClinicalTrials.com","CONTACT","855-907-3286","Clinical.Trials@bms.com",{"name":74,"role":70,"phone":11,"phoneExt":11,"email":11},"First line of the email MUST contain NCT # and Site #.",[76,94,100,110],{"facility":77,"status":78,"city":79,"state":80,"zip":81,"country":82,"countryCode":83,"cosmosGeoPoint":84,"geoPoint":89,"contacts":90},"CenExel iResearch - Decatur","RECRUITING","Decatur","Georgia","30030","United States","US",{"type":85,"coordinates":86},"Point",[87,88],-84.29631,33.77483,{"lat":88,"lon":87},[91],{"name":92,"role":70,"phone":93,"phoneExt":11,"email":11},"Kimball Johnson, Site 0002","404-537-1281",{"facility":95,"status":96,"city":79,"state":80,"zip":81,"country":82,"countryCode":83,"cosmosGeoPoint":97,"geoPoint":99,"contacts":11},"Local Institution - 0003","WITHDRAWN",{"type":85,"coordinates":98},[87,88],{"lat":88,"lon":87},{"facility":101,"status":96,"city":102,"state":103,"zip":104,"country":82,"countryCode":83,"cosmosGeoPoint":105,"geoPoint":109,"contacts":11},"Local Institution - 0001","Austin","Texas","78744",{"type":85,"coordinates":106},[107,108],-97.74306,30.26715,{"lat":108,"lon":107},{"facility":111,"status":112,"city":102,"state":103,"zip":104,"country":82,"countryCode":83,"cosmosGeoPoint":113,"geoPoint":115,"contacts":116},"Local Institution - 0004","NOT_YET_RECRUITING",{"type":85,"coordinates":114},[107,108],{"lat":108,"lon":107},[117],{"name":118,"role":70,"phone":11,"phoneExt":11,"email":11},"Site 0004",{"type":120,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100634818","phase-1-a-phase-1-study-of-navlimetostat-tablet-formulations-100634818",false,"NCT07544628","A Phase 1 Study of Navlimetostat Tablet Formulations","A Phase 1, Open-label, Randomized, 2-Treatment, 2-Period, Crossover Study to Assess the Bioequivalence of Navlimetostat Wet-Granulation Tablet Versus the Dry-Granulation Tablet Formulation in Healthy Adult Female (as Assigned at Birth) Participants Who Are Individuals Not of Childbearing Potential","Inclusion Criteria:\n\n* Participants must be healthy adult INOCBP female with no clinically significant findings on medical history, PE, VS, 12-lead ECGs, or clinical laboratory determinations, as assessed by the investigator.\n* Participants must have BMI of 18.0 to 35.0 kg\u002Fm2.\n* Participants must have adequate laboratory test results for renal and hepatic function, as assessed by the investigator, defined as eGFR ≥ 90 mL\u002Fmin\u002F1.73m2 using the CKD-EPI equation (screening only), and total bilirubin, ALP, GGT, AST, ALT ≤ 1.5 × ULN.\n\nExclusion Criteria:\n\n* Participant must not have any significant acute or chronic medical illness (in the assessment of the investigator).\n* Participant must not have current or recent GI disease: Any gastrointestinal disease within 3 months of study intervention administration that could possibly affect drug absorption, distribution, metabolism, and excretion (eg, bariatric procedure, history of pancreatitis, uncontrolled nausea or vomiting) in the opinion of the investigator.\n* Other protocol defined inclusion\u002Fexclusion criteria applies.",true,"FEMALE","18 Years","55 Years",{"count":133,"type":134},64,"ESTIMATED","INTERVENTIONAL",[137],"PHASE1","This study aims to compare the PK of Navlimetostat after administration of a wet-granulation tablet versus the dry-granulation tablet formulation in healthy adult female",[140],"Healthy Participants",[142,143,144,145,146],"Healthy adult female","Individuals not of childbearing potential","Open label study","Clinical Research Unit","Phase 1","2026-10-06",{"date":149,"type":150},"2026-10-07","ACTUAL",{"date":152,"type":150},"2026-04-27",{"date":154,"type":134},"2026-11-02",{"name":5,"class":6},4]